Drugs

Article	Citations
Acknowledgement to Referees	497
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	472
Targeting DNA Damage Response Deficiency in Thoracic Cancers	288
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	254
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	247
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	224
Eftrenonacog Alfa: A Review in Haemophilia B	196
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	167
Teclistamab: First Approval	164
Aprocitentan: First Approval	156
New Therapies on the Horizon for Primary Biliary Cholangitis	146
Senaparib: First Approval	144
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	142
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	139
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	128
Vorasidenib: First Approval	125
Spesolimab for the Treatment of Generalized Pustular Psoriasis	124
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	108
Epcoritamab: First Approval	103
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	103
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	102
Repotrectinib: First Approval	101
Drugs in Development to Manage Acute Pain	93
Lenacapavir: First Approval	91
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	91

Tolebrutinib: First Approval	90
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	88
Ivarmacitinib Sulfate: First Approval	87
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	85
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses	84
Danicopan: First Approval	82
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	82
Cosibelimab: First Approval	82
Androgenetic Alopecia: Therapy Update	79
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	79
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	78
Acoltremon: First Approval	76
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	76
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	70
Cancer Pain Treatment Strategies in Patients with Cancer	69
Mazdutide: First Approval	68
Sibeprenlimab: First Approval	68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	67
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	66
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	66
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	65
Mosunetuzumab: First Approval	64
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	63
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	63
Pozelimab: First Approval	62
Tovorafenib: First Approval	59
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	58
Correction to: Tapinarof Cream 1%: First Approval	58
Managing Burning Mouth Syndrome: Current and Future Directions	57
The Place of Cannabinoids in the Treatment of Gynecological Pain	57
Pixavir Marboxil: First Approval	57
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	57
Correction to: Prevention and Treatment of Monkeypox	56
Ifupinostat: First Approval	55
Taletrectinib: First Approval	53
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	52
Targeting Inflammation in Bronchiectasis	49
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	48
Dorzagliatin: First Approval	48
Correction to: Concizumab: First Approval	47
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	47
Sunvozertinib: First Approval	47
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	46
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	46
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	46
Correction to: Remdesivir: A Review in COVID-19	45
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	45
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	44
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	43
Gepirone Extended-Release: First Approval	43

Tirzepatide: A Review in Type 2 Diabetes	42
Advances in Immune-Based Approaches for the Cure of HIV Infection	42
Ozoralizumab: First Approval	42
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	41
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	41
Birch Bark Extract: A Review in Epidermolysis Bullosa	41
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades	41
Givinostat: First Approval	41
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	41
Catumaxomab: First Approval	40
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies	40
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review	40
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	40
Correction: Ifupinostat: First Approval	39
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	39
Correction: Teprotumumab: A Review in Thyroid Eye Disease	39
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	38
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	38
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	38
Ensitrelvir Fumaric Acid: First Approval	38
Futibatinib: First Approval	37
Fezolinetant: First Approval	37
Avacincaptad Pegol: First Approval	36
Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects	36
Becotatug Vedotin: First Approval	36
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	36
Antifungal Treatment Regimens as Primary Therapy for Invasive Aspergillosis: A Systematic Review and Network Meta-analysis	35
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale	35
Atrasentan: First Approval	35
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	35
Lotilaner Ophthalmic Solution 0.25%: First Approval	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	34
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	34
Eye Involvement and Management in Inherited Epidermolysis Bullosa	34
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	33
Imetelstat: First Approval	33
Zeprumetostat: First Approval	33
Zastaprazan: First Approval	33
Correction: Iptacopan: First Approval	33
Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review	32
Beremagene Geperpavec: First Approval	32
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	32
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	32
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	32
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	31
Acknowledgement to Referees	31
Managing Pain in Fibromyalgia: Current and Future Options	31
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	31
Mavorixafor: First Approval	30
Etripamil: First Approval	30
Crinecerfont: First Approval	30
Sepiapterin: First Approval	30
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	30
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	30
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	29
Retifanlimab: First Approval	29
EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions	29
Diagnosis and Treatment of AL Amyloidosis	29
Revumenib: First Approval	29
Nogapendekin alfa Inbakicept: First Approval	28
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	28
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	28
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Correction to: Sparsentan: First Approval	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Correction to: Spesolimab: First Approval	27
Onradivir: First Approval	27
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	26
Antibacterials with Novel Chemical Scaffolds in Clinical Development	26
Remdesivir: A Review in COVID-19	26
Keverprazan Hydrochloride: First Approval	26
Correction: Zastaprazan: First Approval	26
Zolbetuximab: First Approval	25
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	25
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	25
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	25
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	25

Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity	25
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	25
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	25
Tradipitant: First Approval	25